-

Shareholder Alert: Robbins LLP Informs Investors of Class Action on Behalf of SVB Financial Group (SIVB) Shareholders Who Previously Held Shares of Boston Private Financial Holdings, Inc. (BPFH)

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs investors that a shareholder filed a class action on behalf of all persons who acquired SVB Financial Group (NASDAQ: SIVB) common stock pursuant to the Registration and Prospectus issued in connection with SVB's July 2021 merger with Boston Private Financial Holdings, Inc. (NASDAQ: BPFH) (the "Merger").

For more information, submit a form, email Aaron Dumas, Jr., or give us a call (800) 350-6003.

What is this Case About: SVB Financial Group (SIVB) Made False and Misleading Statements in its Offering Documents in Connection with its Acquisition of Boston Private Financial Holdings, Inc. (BPFH)

According to the complaint, brought against certain SVB directors and officers and SVB's independent auditor KPMG, LLP, under the Merger, each share of Boston Private stock was converted into the right to receive $2.10 in cash and 0.0228 shares of SVB common stock.

Leading up to the Merger, SVB concentrated a substantial portion of its investment portfolio to longer-term, fixed-rate securities. Because a rise in interest rates reduces the market value of fixed-rate securities, SVB exposed itself to significant interest rate risk. However, SVB failed to disclose this and other risks, including uninsured depositor risk and liquidity risk. Moreover, the Offering Materials framed potential interest rate increases as a positive development for SVB such that it would increase its interest rate spread, allowing SVB to charge more for its loans and buy higher yielding securities at a rate that would outpace the increased interest it would be obligated to pay on its customer deposits. This turned out to be false, and SVB failed to disclose that higher interest rates would reduce the market value of SVB's marketable securities, resulting in material unrealized losses from their decline in market value and released losses if they had to be liquidated.

On March 9, 2023, SVB announced a mid-quarter update that it had sold "substantially all of our Available for Sale (AFS) securities portfolio" resulting in an estimated realized post-tax loss of $1.8 billion. The Company's stock plummeted more than 60% the next day. On March 17, 2023, SVB announced it had filed a voluntary petition under Chapter 11 of the Bankruptcy Code in the U.S. Bankruptcy Court for the Southern District of New York.

What Now: Shareholders who owned Boston Private Financial Holdings, Inc. stock before the Merger and acquired SVB Financial Group pursuant to the Offering Materials may be eligible to participate in the class action against SVB Financial Group. Shareholders who want to act as lead plaintiff for the class should contact Robbins LLP. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

About Robbins LLP: Some law firms issuing releases about this matter do not actually litigate securities class actions; Robbins LLP does. A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. Since our inception, we have obtained over $1 billion for shareholders.

To be notified if a class action against SVB Financial Group settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Aaron Dumas, Jr.
Robbins LLP
5060 Shoreham Pl., Ste. 300
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Robbins LLP

NASDAQ:SIVB

Release Summary
SVB Financial Group (SIVB) Misled Investors in Connection with its Acquisition of Boston Private Financial Holdings, Inc. (BPFH)
Release Versions
$Cashtags

Contacts

Aaron Dumas, Jr.
Robbins LLP
5060 Shoreham Pl., Ste. 300
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Social Media Profiles
More News From Robbins LLP

Robbins LLP Urges GOSS Stockholders to Contact the Firm for Information About the Class Action Against Gossamer Bio, Inc.

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Gossamer Bio, Inc. (NASDAQ: GOSS) securities between June 16, 2025 and February 20, 2026. Gossamer is a clinical stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary hypertension (PH) associated with interstitial lung disease.For more information, submit a form, email att...

Robbins LLP Urges IBRX Stockholders to Contact the Firm for Information About the Class Action Against ImmunityBio, Inc.

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired ImmunityBio, Inc. (NASDAQ: IBRX) securities between January 19, 2026 and March 25, 2026. ImmunityBio is a biotechnology company and ANKTIVA is the Company's lead biologic product. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. What is the class period? January 19, 2026 – March 25, 202...

Robbins LLP Reminds ALDX Investors of the Pending Class Action Lawsuit; Harmed Investors Should Contact the Firm for Information About Leading the Case Against Aldeyra Therapeutics, Inc.

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) securities between November 3, 2023 and March 16, 2026. Defendant Aldeyra describes itself as a “biotechnology company devoted to discovering innovative therapies designed to treat immune-mediated diseases.” Pertinent to this action is reproxalap, which is a novel reactive aldehyde species (RASP) inhib...
Back to Newsroom